Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis

CMAJ. Canadian Medical Association Journal

Volumn 175, Issue 1, 2006, Pages 48-51

  Hodsman, Anthony ^a,d   Papaioannou, Alexandra ^b   Cranney, Ann ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; CANADA; CLINICAL TRIAL; COST UTILITY ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HUMAN; MEDICAL SOCIETY; MENOPAUSAL SYNDROME; NOTE; OSTEOPOROSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; TREATMENT DURATION; VERTEBRA FRACTURE; DRUG INTERACTION; FEMALE; FRACTURE; LITERATURE;

BONE DENSITY CONSERVATION AGENTS; CANADA; DIPHOSPHONATES; DRUG INTERACTIONS; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; PARATHYROID HORMONE; PRACTICE GUIDELINES; REVIEW LITERATURE; TERIPARATIDE;

EID: 33745925572     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060624     Document Type: Note

References (10)

1. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(10 Suppl):S1-S34.
2. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
3. Cranney A, Papaioannou A, Zytaruk N, et al; Clinical Guidelines Committee of Osteoporosis Canada. Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ 2006;175(1):52-9.
4. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
5. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postemopausal osteoporosis. JAMA 1999;282:1344-52.
6. Reginster IY, Minne HW, Sorenson OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
7. Hodsman AB, Bauer DC, Dempster D, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703.
8. Canadian Expert Drug Advisory Committee (CEDAC). CEDAC final recommendation on reconsideration and reasons for recommendation: teriparatide (Forteo™ - Eli Lilly Canada Inc.). Ottawa: Canadian Agency for Drugs and Technologies in Health; 2004. Available: www.cadth.ca/media/cdr/complete/ cdr_complete_Forteo_2004Dec22.pdf (accessed 2006 June 8).
9. Schechtman E. Odds ratio, relative risk, absolute risk reduction, and the number needed to treat - Which of these should we use? Value Health 2002;5:431-6.
10. National Institute for Health and Clinical Excellence. Osteoporosis - secondary prevention: the clinical effectiveness and cost effectiveness of technologies for the secondary prevention of osteoporotic fractures in postmenopausal women [Technology Appraisal no TAo87]. London (UK): National Institute for Health and Clinical Excellence; 2005. Available: www.nice.org.uk/page.aspx?o=TAo87 (accessed 2006 Jun 5).